Rallybio Employees

28 people indexed:

Rallybio Company Information

Rallybio is a biopharmaceutical company headquartered in New Haven, CT, with an additional location in Farmington, CT. The company focuses on developing therapies for rare diseases and has a diversified portfolio of product candidates. Rallybio conducts multinational clinical trials and has a pipeline targeting rare diseases in areas such as hematology, immuno-inflammation, maternal fetal health, ophthalmology, and metabolic disorders. Key products include RLYB212, a clinical-stage therapy aimed at preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT); RLYB116, a C5 inhibitor for diseases caused by complement dysregulation; and RLYB114, which targets ophthalmic diseases through C5 inhibition. Additionally, RLYB331 is a preclinical candidate for treating anemia associated with iron overload disorders, and the ENPP1 Program focuses on developing a small molecule inhibitor for Hypophosphatasia (HPP). Rallybio collaborates with academic clinical centers and industry leaders worldwide.

report flag Report inaccurate information
report flag Report inaccurate information

Companies similar to Rallybio

Disc Medicine develops new therapies for rare blood disorders, focusing on hematologic diseases and conducting clinical trials to evaluate drug efficacy.

People indexed

Blueprint Medicines is a biopharmaceutical company that develops and commercializes innovative therapies, including the approved medicine AYVAKIT/AYVAKYT, focusing on allergy/inflammation and oncology/hematology.

People indexed
Unlock exclusive insights

Sign up to reveal more information.

loader Sign up for free